Literature DB >> 21900645

Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.

Marcia Venegas-Pont1, Keisa W Mathis, Radu Iliescu, William H Ray, Porter H Glover, Michael J Ryan.   

Abstract

Inflammation and immune system dysfunction contributes to the development of cardiovascular and renal disease. Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that carries a high risk for both renal and cardiovascular disease. While hemodynamic changes that may contribute to increased cardiovascular risk have been reported in humans and animal models of SLE, renal hemodynamics have not been widely studied. The renin-angiotensin system (RAS) plays a central role in renal hemodynamic control, and although RAS blockade is a common therapeutic strategy, the role of RAS in hemodynamic function during SLE is not clear. This study tested whether mean arterial pressure (MAP) and renal hemodynamic responses to acute infusions of ANG II in anesthetized animals were enhanced in an established female mouse model of SLE (NZBWF1). Baseline MAP was not different between anesthetized SLE and control (NZWLacJ) mice, while renal blood flow (RBF) was significantly lower in mice with SLE. SLE mice exhibited an enhanced pressor response and greater reduction in RBF after ANG II infusion. An acute infusion of the ANG II receptor blocker losartan increased RBF in control mice but not in mice with SLE. Renin and ANG II type 1 receptor expression was significantly lower, and ANG II type 2 receptor expression was increased in the renal cortex from SLE mice compared with controls. These data suggest that there are fewer ANG II receptors in the kidneys from mice with SLE but that the existing receptors exhibit an enhanced sensitivity to ANG II.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900645      PMCID: PMC3213953          DOI: 10.1152/ajpregu.00079.2011

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  53 in total

1.  NZB/NZW mice as a model of systemic lupus erythematosus.

Authors:  E L Dubois; R E Horowitz; H B Demopoulos; R Teplitz
Journal:  JAMA       Date:  1966-01-24       Impact factor: 56.272

2.  Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis.

Authors:  A Parsa; D H Lovett; E A Peden; Lingxiang Zhu; M F Seldin; L A Criswell
Journal:  Genes Immun       Date:  2005-05       Impact factor: 2.676

3.  Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): lack of association with the angiotensin-converting enzyme gene polymorphism.

Authors:  Y Molad; E Gal; N Magal; J Sulkes; M Mukamel; A Weinberger; S Lalazari; M Shohat
Journal:  Semin Arthritis Rheum       Date:  2000-10       Impact factor: 5.532

4.  The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone.

Authors:  M Macanovic; D Sinicropi; S Shak; S Baughman; S Thiru; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1996-11       Impact factor: 4.330

5.  Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity.

Authors:  Maki Urushihara; Shuji Kondo; Shoji Kagami; Hiroyuki Kobori
Journal:  Am J Nephrol       Date:  2010-02-15       Impact factor: 3.754

6.  Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice.

Authors:  H Herlitz; A Tarkowski; C Svalander; R Volkmann; G Westberg
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

7.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

8.  Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice.

Authors:  Guillermo Pérez De Lema; Cor De Wit; Clemens D Cohen; Elena Nieto; Ana Molina; Bernhard Banas; Bruno Luckow; Ana B Vicente; Francisco Mampaso; Detlef Schlöndorff
Journal:  J Pharmacol Exp Ther       Date:  2003-09-03       Impact factor: 4.030

9.  Angiotensin-converting enzyme gene polymorphism in Kuwaiti patients with systemic lupus erythematosus.

Authors:  A M Al-Awadhi; M Z Haider; P N Sharma; E A Hasan; F Botaiban; A Al-Herz; I Nahar; H Al-Enezi; K Al-Saeid
Journal:  Clin Exp Rheumatol       Date:  2007 May-Jun       Impact factor: 4.473

10.  Functional relationships in the nephrotic syndrome.

Authors:  A B Geers; H A Koomans; J C Roos; P Boer; E J Dorhout Mees
Journal:  Kidney Int       Date:  1984-09       Impact factor: 10.612

View more
  24 in total

Review 1.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

2.  Preventing autoimmunity protects against the development of hypertension and renal injury.

Authors:  Keisa W Mathis; Kedra Wallace; Elizabeth R Flynn; Christine Maric-Bilkan; Babbette LaMarca; Michael J Ryan
Journal:  Hypertension       Date:  2014-07-14       Impact factor: 10.190

3.  Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus.

Authors:  Erin B Taylor; Jennifer M Sasser; Kenji J Maeda; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

Review 4.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

5.  Enhanced hemodynamic responses to angiotensin II in diabetes are associated with increased expression and activity of AT1 receptors in the afferent arteriole.

Authors:  Jie Zhang; Helena Y Qu; Jiangping Song; Jin Wei; Shan Jiang; Lei Wang; Liqing Wang; Jacentha Buggs; Ruisheng Liu
Journal:  Physiol Genomics       Date:  2017-08-25       Impact factor: 3.107

6.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 7.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

8.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

9.  17β-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosus.

Authors:  Emily L Gilbert; Keisa W Mathis; Michael J Ryan
Journal:  Hypertension       Date:  2013-12-23       Impact factor: 10.190

10.  Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.

Authors:  Elena L Dent; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.